Factors Associated With Weight Gain in People Treated With DolutegravirLucia Taramasso, Antonio Di Biagio, Paolo Bonfanti et al.|Open Forum Infectious Diseases|2020Cited by 70
<p>The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile</p>Nicola Squillace, Paolo Bonfanti, Elena Ricci et al.|Drug Design Development and Therapy|2020Cited by 36
<p>Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project</p>Paola Bagella, Giordano Madeddu, Nicola Squillace et al.|Infection and Drug Resistance|2019Cited by 28
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational StudyLucia Taramasso, Andrea De Vito, Elena Ricci et al.|AIDS Patient Care and STDs|2021Cited by 25
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) projectNicola Squillace, Elena Ricci, Tiziana Quirino et al.|PLoS ONE|2017Cited by 22